Cellular effects of dopamine - Beyond oxidative mechanisms

Parkinsonism and Related Disorders

Volumn 8, Issue 6, 2002, Pages 433-437

  Pifl, Christian ^a   Kattinger, Alexandra ^a   Reither, Harald ^a   Hornykiewicz, Oleh ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cell cycle; Dopamine; Iron; L DOPA; Neurodegeneration; Oxidative stress; Parkinson's disease

Indexed keywords

DOPAMINE;

ARTICLE; BRAIN NERVE CELL; CELL CULTURE; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; DOPAMINE UPTAKE; DRUG EFFECT; GROWTH INHIBITION; HUMAN; HUMAN CELL; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA CELL; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

CELL COUNT; CELL SURVIVAL; DNA, COMPLEMENTARY; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; INTRACELLULAR FLUID; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NEUROBLASTOMA; OXIDANTS; OXIDATIVE STRESS; TUMOR CELLS, CULTURED;

EID: 0036767658     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(02)00028-7     Document Type: Article

References (22)

1. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol Rev. 78:1998;189-225.
2. Ziv I., Melamed E., Nardi N., Luria D., Achiron A., Offen D., Barzilai A. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci Lett. 170:1994;136-140.
3. Masserano J.M., Gong L., Kulaga H., Baker I., Wyatt R.J. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. Mol Pharmacol. 50:1996;1309-1315.
4. Offen D., Ziv I., Gorodin S., Malik Z., Barzilai A., Melamed E. Dopamine-induced programmed cell death in mouse thymocytes. Biochem Biophys Acta. 1268:1995;171-177.
5. Offen D., Ziv I., Sternin H., Melamed E., Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp Neurol. 141:1996;32-39.
6. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease. Evidence supporting it. Ann Neurol. 32:1992;804-812.
7. Langston J.W. The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology. 47:(Suppl. 3):1996;S153-S160.
8. Pifl C., Zezula J., Spittler A., Kattinger A., Reither H., Caron M.G., Hornykiewicz O. Antiproliferative action of dopamine and norepinephrine in neuroblastoma cells expressing the human dopamine transporter. FASEB J. 15:2001;1607-1609.
9. Pifl C., Hornykiewicz O., Giros B., Caron M.G. Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter. J Pharmacol Exp Ther. 277:1996;1437-1443.
10. Carter W.O., Narayanan P.K., Robinson J.P. Intracellular hydrogen peroxide and superoxide anion detection in endothelial cells. J Leukoc Biol. 55:1994;253-258.
11. Terada N., Lucas J.J., Gelfand E.W. Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb) and p53, during cell cycle progression of normal human T cells. J Immunol. 147:1991;698-704.
12. Grol C.J. Chemistry of dopamine. Horn A.S., Korf J., Westerink B.H.C. The neurobiology of dopamine. 1979;7-27 Academic Press, London.
13. Richardson D.R. Potential of iron chelators as effective antiproliferative agents. Can J Physiol Pharmacol. 75:1997;1164-1180.
14. Nyholm S., Mann G.J., Johansson A.G., Bergeron R.J., Greaslund A., Thelander L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem. 268:1993;26200-26205.
15. Ross M.E. Cell division and the nervous system: regulating the cycle from neural differentiation to death. Trends Neurosci. 19:1996;62-68.
16. Farinelli S.E., Greene L.A. Cell cycle blockers mimosine, ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support. J Neurosci. 16:1996;1150-1162.
17. Park D.S., Morris E.J., Greene L.A., Geller H.M. G1/S cell cycle blockers and inhibitors of cyclin-dependent kinases suppress camptothecin-induced neuronal apoptosis. J Neurosci. 17:1996;1256-1270.
18. Rubin L.L., Philpott K.L., Brooks S.F. The cell cycle and cell death. Curr Biol. 3:1993;391-394.
19. Hornykiewicz O. Brain neurotransmitter changes in Parkinson's disease. Marsden C.D., Fahn S. Movement disorders. 1981;41-58 Butterworth Scientific, London.
20. Di Monte D.A., DeLanney L.E., Irwin I., Royland J.E., Chan P., Jakowec M.W., Langston J.W. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys. Brain Res. 738:1996;53-59.
21. Jenner P.G., Brin M.F. Levodopa neurotoxicity: experimental studies versus clinical relevance. Neurology. 50:(Suppl. 6):1998;S39-S43.
22. Gwinn-Hardy K., Evidente V.G., Waters C., Muenter M.D., Hardy J. L-dopa slows the progression of familial parkinsonism. Lancet. 353:1999;1850-1851.